BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...

Emergent BioSolutions (NYSE:EBS) has entered into an agreement for the exclusive commercial rights in the U.S. and Canada for ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the sale of ...

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it attempts to reestablish its unique role as a drug developer combating u | ...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the ...

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between ...

HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Emergent BioSolutions (EBS) announces that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma ...

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...